Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Clinical trial NCT07219459 · RECRUITING

Trial details

NCT number: NCT07219459
Sponsor: CatalYm GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable or Metastatic Hepatocellular Carcinoma Child-Pugh A Hepatocellular Carcinoma Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Start date: 2026-03-19
Primary completion: 2029-09-01
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.